Patent Application
20190274964
The invention relates to an immediate and sustained release composition, a dose unit or a two compartment package comprising the composition as well as use and a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract.
Diarrhea is an intestinal disorder that is characterized by an increase in the frequency of watery bowel movements. It may result from a variety of causes including bacteria or viral induced diarrhea. Food intolerance caused by allergy or the consumption of foods such as fatty or spicy foods may result in diarrhea. Food poisoning may also lead to diarrhea. In some instances, diarrhea may be a symptom of other conditions and diseases. One example is the irritable bowel syndrome (IBS). A patient with IBS typically presents clinically with one of three variants: i) chronic abdominal pain and constipation (also known as spastic colitis); ii) chronic intermittent diarrhea, often without pain; or iii) both features, in an alternating cycle of constipation and diarrhea.
Diarrhea is symptomatic of an intestinal or other bodily function disorder. Various prescription and nonprescription products can be taken for relief. However, many of these products provide relief with some side effects.
Racecadotril is used in the treatment of diarrhea. It reduces (i) hypersecretion of water and electrolytes into the intestinal lumen, (ii) the incidence and duration of acute diarrhea and (iii) diarrhea-associated symptoms.
Simethicone is an orally administered anti-foaming agent used to reduce bloating, discomfort or pain caused by excessive gas, mainly swallowed air, with small amounts of hydrogen and methane in the stomach or intestines.
US2016/0120834 discloses a method to manufacturing cadotril particles that could be formulated either as an immediate or a sustained release formulation, i.e., tablet or liquid formulation as shown in the examples.
There is a need for new products containing either racecadotril or an enantiomer of racecadotril or mixtures thereof or a combination with simethicone to be able to provide new products on the market which aim at helping consumers suffering from a disorder or disease within the gastro intestinal tract.
The invention relates to the development of new improved compositions comprising racecadotril or an enantiomer of racecadotril or mixtures thereof alone or in combination with Simethicone.
It has surprisingly been found that such a composition will provide an immediate as well as s sustained release profile, which enables the possibility to get a faster relief in a subject suffering from a disease or disorder in the gastro intestinal tract as well as a sustained relief which reduces the number of doses to be taken daily. In addition the use of few and less toxic excipients it is as well possible to obtain a composition that is not harmful for the subject. Further the formulations with oil allow better taste masking of the active ingredient, which enables direct administration into the mouth.
In a first aspect the invention relates to an immediate and sustained release composition or a two compartment package comprising a first immediate release composition comprising at least racecadotril or an enantiomer of racecadotril or mixtures thereof in an amount of at most 10% w/w and at least one liquid-lipid excipient present in an amount of from at least 90% w/w of the total amount of the first composition and s second sustained release composition comprising at least racecadotril or an enantiomer of racecadotril or mixtures thereof in an amount of from about 10% to about 40% w/w and at least one liquid-lipid excipient present in an amount of about 60% to about 90% w/w of the total amount of the second composition.
In a second aspect the invention relates to a an immediate and sustained release composition or a two compartment package comprising a first immediate release composition comprising at least racecadotril or an enantiomer of racecadotril or mixtures thereof in an amount of at most 10% w/w of the total amount of the first composition and at least one liquid-lipid excipient present in an amount of from at least 40% w/w of the total amount of the first composition and simethicone in an amount of at most 50% w/w of the total amount of the first composition and second sustained release composition comprising at least racecadotril or an enantiomer of racecadotril or mixtures thereof in an amount of from about 10% to about 50% w/w of the total amount of the second composition at least one liquid-lipid excipient present in an amount of from about 10% to about 80% w/w of the total amount of the second composition and simethicone in an amount of about 10% to about 60% w/w of the total amount of the second composition.
Such a composition or package will give rise to the possibility to provide higher concentrations/doses of racecadotril or an enantiomer of racecadotril or mixtures thereof compared to what is possible today as well as due to the increased bioavailability decrease the concentration/dose. By providing a prolonged release profile it will secure that drug level will be kept within the effective concentration range for a longer period of time. Such prolonged release profile makes it possible to reduce dosing frequency as well as having once or twice daily dosing instead of three times daily dosing, which most products provide on the market today. In addition, the prolonged release may help to avoid too high plasma concentration, which could lead to increased risk for adverse or unwanted effects. There is no product available on the market today providing such a product and which solves the above identified problems.
Finally, the invention relates to a method of using the compositions and packages as defined above and below in the application for the treatment of a subject suffering from a disease or disorder in the gastro intestinal tract, wherein the semi-solid could be co-administrated with one or more dietary fibre products.
In the context of the present application and invention the following definitions apply:
Racecadotril also known as acetorphan, chemically known as benzyl N-[3-(acetylthio)-2 benzylpropanoyl] glycinate is an anti-diarrheal drug which acts as a peripherally acting enkephalinase inhibitor. It has an anti-secretory effect and used to treat diarrhoea. It reduces the secretion of water and electrolytes into the intestine. Racecadotril is a prodrug and it is hydrolysed to its active metabolite, thiorphan following intravenous or oral administration. Racecadotril may be in the R-form or S-form or a mixture thereof. Thiorphan is the active metabolite of racecadotril, which exerts the bulk of its inhibitory actions on enkephalinase.
The term “racemic” is intended to mean an equimolar mixture of enantiomers.
The term “enantiomer” is intended to mean a stereoisomer that is related like an object and its mirror reflection. Enantiomers occur only with compounds whose molecules are chiral, that is, with molecules that are not superposable on their mirror reflections. Separate enantiomers rotate the plane of polarized light and are said to be optically active. They have equal but opposite specific rotation. Examples of enantiomers are ecadotril and dexecadotril.
As used herein, the term “sustained release” (“SR”) refers to compositions which are characterized by having at least one of the active components (i.e., racecadotril) having a release over a period of at least about 5 hours. As with formulations described herein, “sustained release” may be achieved by a single formulation containing both “immediate release” components and a “sustained release” (i.e., release for about 5 hours). The release profile may be assessed via in vitro dissolution using techniques known to those of skill in the art (e.g., USP basket method, Paddle Method, channel flow method, or other methods known in the literature). The release profile can be assessed in vivo (e.g., for bioavailability determinations), using plasma concentrations to assess maximum plasma concentration (Cmax) and area under the curve (AUC). Such assays are well known to those of skill in the art.
The term “immediate release” (“IR”) is intended to mean the release of an active ingredient (e.g., racecadotril) from a pharmaceutical formulation where the rate of release of the active pharmaceutical ingredient from the pharmaceutical formulation is not retarded by means of a controlled release matrix or other such means and where the components of the pharmaceutical formulation are designed such that, upon ingestion, maximum exposure of said active pharmaceutical ingredient to body tissues occurs in the minimum period of time. As described herein, an “immediate release” component preferably releases in less than 1 hour.
The term Medium Chain Triglyceride(s) (MCTs) is/are intended to mean triglycerides whose fatty acids have an aliphatic tail of 6-12 carbon atoms.
The fatty acids found in MCTs are called medium-chain fatty acids (MCFAs). Like all triglycerides, MCTs are composed of a glycerol backbone and three fatty acids.
The term “substantially free from water or free from water” is intended to mean that the content of water present in the composition is less than about 2 wt. % based on the total wt. % of the composition, such as less than 1.5, 1, 0.5, 0.4, 0.3, 0.2 or less than 0.1 or totally free from water, i.e., 0 wt % based on the total wt. % of the composition.
The term “substantially free from non-ionic surfactants or free from non-ionic surfactants” is intended to mean that the content of the non-ionic surfactant present in the composition is less than about 2 wt. % based on the total wt. % of the composition, such as less than 1.5, 1, 0.5, 0.4, 0.3, 0.2 or less than 0.1 or totally free from surfactant, i.e., 0 wt. % based on the total wt. % of the composition. The definition of a non-ionic surfactant is well-known for a person skilled in the art as being compounds that lower the surface tension (or interfacial tension) between two liquids or between a liquid and a solid. Non-ionic surfactants are amphiphilic molecules that have both a hydrophobic group non-polar “tail” and a hydrophilic group polar but uncharged “head”.
The term “% w/w” is intended to mean the percentage of an ingredient(s)/the total percentage by weight of the composition (100%).
The term “bioavailability” is intended to mean, the rate and extent to which the active substance or active moiety is absorbed from a pharmaceutical form and becomes available at the site of action. Bioavailability of oral racecadotril is assessed by monitoring concentrations of racecadotrils active metabolite (thiorphan) in the general circulation.
A “dosage”, “dosage form”, “dose unit” or “dose” as used herein means the amount of a pharmaceutical formulation comprising therapeutically active agent(s) administered at a time. “Dosage”, “dosage form”, “dose unit” or “dose” includes administration of one or more units of pharmaceutical formulation administered at the same time.
The invention relates to a composition comprising an immediate and a sustained release composition
In one embodiment the first immediate release composition comprises at least racecadotril or an enantiomer of racecadotril or mixtures thereof in an amount of at most 10% w/w, such as 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.5% w/w of the total amount of the first composition and at least one liquid-lipid excipient present in an amount of from at least 90% w/w, such as 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5% w/w of the total amount of the first composition.
The immediate release composition may be a Self-Emulsifying Nano-Emulsion of racecadotril selected from the formulations disclosed in US20150342882, i.e., contains surfactants. The immediate release composition may for example contain one or more surfactants, such as Polyoxyl 60 hydrogenated castor oil (sold under the trade mark CREMOPHOR RH 60).
The second sustained release composition comprising at least racecadotril or an enantiomer of racecadotril or mixtures thereof in an amount of from about 10% to about 40% w/w, such as about 10 to about 30, about 10 to about 20, about 10 to about 35, about 20 to about 30, about 20 to about 35, such as about 10, 15, 20, 25, 30, 35 or 4% w/w of the total amount of the second composition and at least one liquid-lipid and/or polyol and/or glycerol and/or propylene glycol excipient present in an amount of about 60% to about 90% w/w, such as about 60 to about 80, about 60 to about 70, about 70 to about 90, about 70 to about 80% w/w of the total amount of the second composition.
In another embodiment the first immediate release composition comprises at least racecadotril or an enantiomer of racecadotril or mixtures thereof in an amount of at most 10% w/w, such as 9, 8, 7, 6, 5, 4, 3, 2, 1, 1.5% w/w of the total amount of the first composition and at least one liquid-lipid and/or polyol and/or glycerol and/or propylene glycol excipient present in an amount of from at least 90% w/w, such as 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5% w/w of the total amount of the first composition. In addition the first immediate release composition comprises simethicone in an amount of at most 50% w/w, such as 45, 40, 35, 30, 25, 20, 15, 10, 5% w/w of the total amount of the first composition.
The second sustained release composition comprising at least racecadotril or an enantiomer of racecadotril or mixtures thereof in an amount of from about 10% to about 40% w/w, such as about 10 to about 30, about 10 to about 20, about 10 to about 35, about 20 to about 30, about 20 to about 35, such as about 10, 15, 20, 25, 30, 35 or 4% w/w of the total amount of the second composition and at least one liquid-lipid and/or polyol and/or glycerol and/or propylene glycol excipient present in an amount of about 60% to about 90% w/w, such as about 60 to about 80, about 60 to about 70, about 70 to about 90, about 70 to about 80% w/w of the total amount of the second composition. In addition the second sustained release composition comprises simethicone in an amount of about 10% to about 60% w/w, such as about 15 to about 50, about 40 to about 50% w/w of the total amount of the second composition.
Simethicone may be available from DOW CORNING® Q7-2243 LVA, SIMETHICONE USP, or DOW CORNING Antifoam M.
The liquid-lipid excipient used in the immediate and sustained release composition in any of the compartment is at least one medium chain triglyceride (MCT) or at least one oil containing medium chain triglycerides or a mixture thereof.
The immediate and sustained release composition may be substantially free from non-ionic surfactants and/or being substantially free from water as defined above. By not utilizing any non-ionic surfactant, there will be no problem with unpleasant taste, irritation or toxic effect will occur which is common upon using surfactants.
The at least one medium chain triglyceride (MCT), i.e., an ester of glycerol and a medium chain fatty acid or a natural oil containing medium chain fatty acids, wherein the medium chain fatty acids are selected from the group consisting of caprylic acid (C8), caproic (C6) acid, capric acid (C10), lauric acid (C12) or mixture thereof. One example being that the medium chain triglyceride is an ester of glycerol and one or more medium chain fatty acids being caprylic or capric acid or a mixture thereof. Other examples are found in table 1.
The Medium chain fatty acid (MCFA), is one or more medium chain fatty acids selected from the group consisting of caprylic acid (C8), caproic (C6) acid, capric acid (C10), lauric acid and esters of caprylic acid (C8), caproic (C6) acid, capric acid (C10), lauric acid. The MCFA may be a mixture of caprylic and capric acid. The amount of the MCFA's in a MCT may be C6<2.0%, C8 about 50-80%, C10 about 20-50%. One example is C12<3.0% and C14<1.0% and the total amount of C8 and C10 up to 95% and the water content <0.2%.
Examples of MCTs presented on the market today are shown in table 1 below.
The MCTs shown in table 1 above can be purchased from the following companies. Miglyol 812 from SASOL GmbH, CRODAMOL GTCC from Croda, or Neobees M-5 oil from Stepan and LABRAFAC LIPOPHILE WL 1349 from Gattefosst.
Examples of natural oils that could be used are all natural oils comprising MCTs, such as coconut or palm or palm kernel oils.
The immediate and sustained release compositions may further comprise one or more ingredient(s) selected from the list consisting of coloring agents, antioxidants, flavoring agents, sweeteners, thickeners, emulsifiers, excipients, preservatives and gelling agents.
Additionally, the compositions may comprise one or more fibres, such as dietary fibre which consists of non-starch polysaccharides such as arabinoxylans, cellulose, and many other plant components such as resistant starch, resistant dextrins, inulin, lignin, waxes, chitins, pectins, beta-glucans, and oligosaccharides and other types of carbohydrate that the body can't digest and simply passes through the entire digestive tract. Generally, fibres comes from plant foods: fruits, vegetables, grains, nuts, and legumes such fibre are classified as soluble fibres such as psyllium fibres, others are classified as insoluble fibres like those found in the seeds and skins of fruit as well as whole-wheat bread and brown rice.
The immediate and sustained release composition may further comprise an additional active ingredient. The additional active ingredient may be, a digestive health active ingredient, for example, laxatives, antacids, proton pump inhibitors, anti-gas agents, antiemetics, H2 blockers, a second antidiarrheal agent, antispasmotic agents or analgesic agents and the like. Examples of additional agents includes loperamide, a-galactosidase enzyme, calcium carbonate, aluminum hydroxide and magnesium hydroxide.
The dosage form of the immediate and sustained release composition may be capsules.
The invention further relates to a two compartment package comprising racecadotril or an enantiomer of racecadotril or mixtures thereof with or without simethicone.
In a first embodiment the two compartment package comprises a first immediate release composition in a first compartment comprising at least racecadotril or an enantiomer of racecadotril or mixtures thereof in an amount of at most 10% w/w, such as 9, 8, 7, 6, 5, 4, 3, 2, 1, 1.5% w/w of the total amount of the first composition and at least one liquid-lipid excipient present in an amount of from at least 90% w/w, such as 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5% w/w of the total amount of the first composition present in the first compartment and a second composition in a second compartment comprising at least racecadotril or an enantiomer of racecadotril or mixtures thereof in an amount of from about 10% to about 40% w/w, such as about 10 to about 30, about 10 to about 20, about 10 to about 35, about 20 to about 35, such as about 10, 15, 20, 25, 30, 35 or 4% w/w of the total amount of the second composition and at least one liquid-lipid and/or polyol and/or glycerol and/or propylene glycol excipient present in an amount of about 60% to about 90% w/w, such as about 60 to about 80, about 60 to about 70, about 70 to about 90, about 70 to about 80% w/w of the total amount of the second composition.
In a further embodiment, the invention further relates to a two compartment package comprising racecadotril or an enantiomer of racecadotril or mixtures thereof with simethicone in a first immediate release composition in a first compartment and a second sustained release composition in a second compartment.
The first immediate release composition comprises at least racecadotril or an enantiomer of racecadotril or mixtures thereof in an amount of at most 10% w/w, such as 9, 8, 7, 6, 5, 4, 3, 2, 1, 1.5% w/w of the total amount of the first composition and at least one liquid-lipid and/or polyol and/or glycerol and/or propylene glycol excipient present in an amount of from at least 90% w/w, such as 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5% w/w of the total amount of the first composition. In addition, the first immediate release composition comprises simethicone in an amount of at most 50% w/w, such as 45, 40, 35, 30, 25, 20, 15, 10, 5% w/w of the total amount of the first composition.
The second sustained release composition comprising at least racecadotril or an enantiomer of racecadotril or mixtures thereof in an amount of from about 10% to about 40% w/w, such as about 10 to about 30, about 10 to about 20, about 10 to about 35, about 20 to about 35, such as about 10, 15, 20, 25, 30, 35 or 4% w/w of the total amount of the second composition and at least one liquid-lipid and/or polyol and/or glycerol and/or propylene glycol excipient present in an amount of about 60% to about 90% w/w, such as about 60 to about 80, about 60 to about 70, about 70 to about 90, about 70 to about 80% w/w of the total amount of the second composition. In addition, the second sustained release composition comprises simethicone in an amount of about 10% to about 60% w/w, such as about 15 to about 50, about 40 to about 50% w/w of the total amount of the second composition.
Further components/ingredients present in the package are equal to those disclosed in the composition above.
The two compartment package may be a stick pack, pouch or a sachet.
Racecadotril or an enantiomer of racecadotril or mixtures thereof is/are present in the unit dose or the two compartment package in an amount from about 5 mg to about 200 mg, such as about 5 mg or about 100 mg and simethicone is present in an amount from about 50 to about 1500 mg, such as about 50 to about 1000 mg, such as about 50 to about 500 mg, such as about 50 to about 100 mg, such as about 2 mg to about 150 mg, such as about 6.25 or about 125 mg.
Further the invention relates to use of the immediate and sustained release composition or the two compartment packaged defined above for the treatment of a subject suffering from a disease or disorder in the gastro intestinal tract, such as Irritable Bowel Syndrome (IBS), such as diarrhea and/or constipation and/or bloating, discomfort or pain caused by excessive gas.
Finally, the invention relates to a method of treatment of a subject suffering from a disease or disorder in the gastro intestinal tract, such as IBS, such as diarrhea and/or constipation and/or bloating, discomfort or pain caused by excessive gas.
Following examples are intended to illustrate, but not to limit, the invention in any manner, shape, or form, either explicitly or implicitly.
Racecadotril powder is available from Sigma-Aldrich, Triglycerides, Medium-Chain PhEur (MCT), Crodamol GTCC-LQ-(MV), was obtained from Croda, Simethicone Q7-2243 LVA, SIMETHICONE USP was obtained from DOW CORNING®.
Racecadotril is weighed in a scintillation vial.
The MCT is weighed and added in the same vial.
The mixture is heated in a water bath at 80° C. (the vial is closed to avoid direct contact with water or water vapor) and mixed using stirred using vortex or homogenizer to dissolve racecadotril and achieve a clear homogenous solution.
Cooling down at room temperature
Simethicone can be added either before heating and mixing or to be mixed at the end.
Racecadotril is weighed in a scintillation vial.
The MCT (obtained from Croda) is weighed and added in the same vial.
The mixture is heated in a water bath at 80° C. (the vial is closed to avoid direct contact with water or water vapor) and mixed using stirred using vortex or homogenizer to dissolve racecadotril and achieve a clear homogenous solution.
Cooling down at room temperature with continuous mixing in order to obtain a semi-solid formulation.
Simethicone can be added either before heating and mixing or to be mixed with the semisolid at the end.
Preparation of bulk IR Self-Emulsifying Nano-Emulsion All the ingredients were weighed into a suitable glass bottle with magnetic stir bar and mixed until a clear solution was obtained (˜30 hours).
Dissolution test was accomplished using paddle dissolution tester. Liquid formulation was added by a syringe whereas sinker baskets JP13 were used for capsules of semisolid and powder formulations. Dissolution media was a phosphate buffer pH 6.2 with 1% SDS at 37° C. temperature.
Samples of 1.5 ml were taken and filtered using Nylon membrane 0.45 μm. Racecadotril concentration was determined using Ultra Performance Liquid Chromatography UPLC.
Commercially available Balsamic Mint flavor and Sucralose is available from Sigma-Aldrich,
racecadotril Combination formulation (Example 1C) liquid immediate release (IR) plus semisolid sustained release (SR) in comparison with semisolid sustained release (SR) alone, Vaprino®100 mg capsule was used as reference.
The induction of diarrhea with castor oil results from the action of ricinoleic acid formed by hydrolysis of the oil (Iwao and Terada, 1962, J. Pharmacol 12:137-145). Ricinoleic acid produces changes in the transport of water and electrolytes resulting in a hypersecretory response (Ammon et al., 1974, J. Clin. Invest. 53:374-379). In addition to hypersecretion, ricinoleic acid sensitizes the intramural neurons of the gut. The castor oil test (Niemegeers et al., 1984, Drug Dev. Res. 1:1-20) has widely been used to study effects of antidiarrheals in various preclinical settings. Racecadotril and thiorphan have previously been shown to inhibit castor-oil induced diarrhea in rats (Marcais-Collado et al., 1987, Eur. J. Pharmacol. 144:125-132). Intravenous administration of thiorphan resulted in a dose-dependent protection against diarrhea as measured by cumulative stool weight and time to onset. Protection was most prominent during the first two hours following challenge with castor oil. Similarly, pre-treatment with racecadotril (p.o.), resulted in a reduction in cumulative stool weight following challenge with castor oil. Time to onset was also significantly delayed, although a dose-response relationship could not be established.
The castor oil test described by Niemeegers et al. (1984) was used with small modifications. Following the various treatments, overnight fasted rats received a standard dose of castor oil administered orally by gavage and were caged individually. The time to onset of diarrhea and cumulative stool weights were noted during an 8 h observation period.
Male Sprague Dawley rats were obtained from Janvier Labs and housed as described in section 9.2.2. The rats were acclimatized to the housing conditions for at least 7 days before the start of experiments. The approximate weight of animals was 300 g at performance of experiments.
Food (but not water) was withheld 16 h prior to dosing of castor oil (challenge). For induction of diarrhea, the rats received 2 ml of castor oil, delivered by oral gavage. After the challenge, the rats were placed in individual cages with grilled floor. The rats had access to food from 30 minutes after dosing with castor oil and during the whole observation period. Stools were collected on non-wetting paper placed beneath the grilled floor at predefined time points, weighed and thereafter incubated at 70 C for at least 16 hours for determination of dry weight.
The following parameters were evaluated:
Time to onset (first diarrhea)
Accumulated weight of total stool (wet weight and dry weight)
Treatment
The rats were dosed p.o. with racecadotril/vehicle one hour before challenge with castor oil. The rats were slightly sedated using isofluorane at delivery of the test items. The racecadotril dose of 20 mg/kg body weight was given based on an assumed rat weight 300 g. Animals were weighed before the experiments to allow calculation of the actual delivered dose. 2 ml of saline was delivered by gavage immediately after dosing. Control groups consisting of rats given castor oil only and non-diarrheic rats (given saline instead of castor oil) were included in all experiments. The studies were generally performed over three experimental days and all groups contained rats from all three experimental days to avoid interference from potential day to day variation.
Fasting overnight
Administration of racecadotril
Challenge with castor oil 1 h post dosing
Assessment of
Blood sampling 1 h post dosing to verify uptake
Results:
Significant improved effect for IR+SR (Example 1C-formulation nr. 1) compared to reference (Vaprino®100 mg capsule). SR alone was not significant compared to reference
| Number | Date | Country | Kind |
|---|---|---|---|
| 1651126-3 | Aug 2016 | SE | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/IB2017/055041 | 8/21/2017 | WO | 00 |
